Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Latest Developments for the Treatment of Ataxia Telangiectasia: A Narrative Review Publisher Pubmed



Mehri A1 ; Toosi MB2 ; Tavasoli AR3, 4 ; Saberikarimian M5, 6, 7
Authors
Show Affiliations
Authors Affiliations
  1. 1. Endoscopic and Minimally Invasive Surgery Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
  2. 2. Department of Pediatric Diseases, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
  3. 3. Pediatric Neurology Division, Pediatrics Center of Excellence, Myelin Disorders Clinic, Children’s Medical Center, Tehran University of Medical Sciences, No. 61, Gharib Street, Keshavarz Blvd, Tehran, 1419733151, Iran
  4. 4. Pediatric Headache Program, Barrow Neurological Institute, Phoenix Children’s Hospital, Phoenix, AZ, United States
  5. 5. Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
  6. 6. Department of Medical Genetics and Molecular Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
  7. 7. International UNESCO center for Health-Related Basic Sciences and Human Nutrition, Mashhad University of Medical Sciences, Mashhad, Iran

Source: Cerebellum Published:2024


Abstract

Ataxia telangiectasia (AT), Louis-Bar syndrome, is a rare neurodegenerative disorder caused by autosomal recessive biallelic mutations within the ataxia telangiectasia mutated (ATM) gene. Currently, there are no curative therapies available for this disorder. This review provides an overview of the latest advances in treatment methods including 1- Acetyl-DL-leucine, 2- Bone Marrow Transplantation, 3- Gene Therapy, 4- Dexamethasone, and finally 5- Red Blood Cells (RBCs) as a carrier for dexamethasone (encapsulation of dexamethasone sodium phosphate into autologous erythrocytes, known as EryDex). Most of the treatments under investigation are in the early stages, except for the EryDex System. It appears that the EryDex system and N-Acetyl-DL-Leucine may hold promise as potential treatment options. © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024.
Related Docs
View other Related Docs
1. Ataxia-Telangiectasia: Epidemiology, Pathogenesis, Clinical Phenotype, Diagnosis, Prognosis and Management, Expert Review of Clinical Immunology (2020)
2. Inflammation, a Significant Player of Ataxia–Telangiectasia Pathogenesis?, Inflammation Research (2018)
3. Atm Expression and Activation in Ataxia Telangiectasia Patients With and Without Class Switch Recombination Defects, Journal of Clinical Immunology (2025)
4. Atypical Ataxia Presentation in Variant Ataxia Telangiectasia: Iranian Case-Series and Review of the Literature, Frontiers in Immunology (2022)
5. Ataxia-Telangiectasia: A Review of Clinical Features and Molecular Pathology, Pediatric Allergy and Immunology (2019)
6. The Spectrum of Atm Gene Mutations in Iranian Patients With Ataxia-Telangiectasia, Pediatric Allergy and Immunology (2021)
7. Cutaneous Granulomatosis and Class Switching Defect As a Presenting Sign in Ataxia-Telangiectasia: First Case From the National Iranian Registry and Review of the Literature, Immunological Investigations (2020)
8. Evaluation of Specific Antibody Responses in Patients With Selective Iga Deficiency and Ataxia Telangiectasia, Endocrine# Metabolic and Immune Disorders - Drug Targets (2022)
Experts (# of related papers)
View all Related Experts
Nima Rezaei (5)
Seyed Mohammad Akrami (3)
Other Related Docs
9. Pulmonary Manifestations of Other Well-Defined Immunodeficiencies, Pulmonary Manifestations of Primary Immunodeficiency Diseases (2018)
10. Immunomodulatory Characteristics of Mesenchymal Stem Cells and Their Role in the Treatment of Multiple Sclerosis, Cellular Immunology (2015)
11. Cancer Trends in Inborn Errors of Immunity: A Systematic Review and Meta-Analysis, Journal of Clinical Immunology (2025)
12. Effect of Class Switch Recombination Defect on the Phenotype of Ataxia-Telangiectasia Patients, Immunological Investigations (2021)
13. Stem Cell Therapy ‒Approach for Multiple Sclerosis Treatment, Archives of Neuroscience (2016)